Gossamer Bio has an option to acquire Respira Therapeutics and its inhaled pulmonary arterial hypertension treatment RT234. Gossamer plans to develop RT234 for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), the same two indications for which it is already developing its own inhaled treatment candidate, seralutinib.
RT234 is an inhaled formulation of vardenafil, a phosphodiesterase-5 inhibitor, the same class of medications to which the approved oral pulmonary arterial hypertension therapies Revatio (sildenafil) and Adcirca (tadalafil) belong. In contrast to these therapies, which are taken once daily, RT234 is designed to be delivered directly to the lungs via a dry-powder inhaler and used as needed for quick symptom relief.
Gossamer Bio has now fully enrolled its Phase 3 PROSERA trial (NCT05934526) testing the treatment candidate seralutinib’s ability to improve exercise capacity in adults with pulmonary arterial hypertension. See our previous article here. Gossamer also expects to launch a global Phase 3 trial called SERANATA (NCT07181382) by year’s end that will primarily evaluate seralutinib’s ability to improve exercise abilities in people with pulmonary hypertension associated with interstitial lung disease. Gossamer is developing seralutinib in collaboration with Chiesi Farmaceutici.
Read more at this link on Pulmonary Hypertension News